Evidence map›Paper›PMID 41379263›Full record

ArticleDiscover oncology2025

Multiple primary cancers with prostate malignant tumor as the initial diagnosis: a case report.

Kai Yang, Jiatong Zhou

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kai YangDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang, People's Republic Of China.
Jiatong ZhouDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang, People's Republic Of China. 1324088@zju.edu.cn.

Funding

National Natural Science Foundation for Young Scientists of China 82504016
6 · The paper itself

Abstract

With the advancement of medical technology and improvements in living standards, the survival time of many cancer patients has been prolonged. However, a significant proportion of these patients develop multiple primary cancers (MPC), which indicates a poorer prognosis. Currently, there are no specific guidelines for managing MPC. This article reports a rare case of an elderly male patient who, during a six-year follow-up period, was diagnosed with four primary tumors in different organs including prostate cancer (first manifestation), renal cancer, bladder cancer, and lung cancer. Genetic testing of tumor tissues revealed an EGFR mutation in the lung cancer tissue and BAP1 gene deletion in the renal cancer tissue. Over the six-year follow-up, the patient underwent radical prostatectomy, partial nephrectomy, transurethral resection of bladder tumor, and radical left lung resection, with good postoperative recovery. This case represents MPC involving three urogenital system tumors and highlights the rare coexistence of EGFR mutation and BAP1 gene deletion across different organ-specific cancers. It underscores the necessity of genetic testing for MPC patients and demonstrates that aggressive management of primary tumors can improve the patient's quality of life. This case provides valuable insights for clinical research and treatment strategies for MPC.

Indexed as

BAP1 lossEGFR mutationMultiple primary cancers

Identifiers

PMID41379263
PMCPMC12804532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.